Zenapax humanized anti-tac monoclonal antibody targeted to interleukin-2 receptors on activated T cells data

PDLI (Mountain View, Calif.) reported Phase I data from 12 recipients of kidney transplants, with only one episode of rejection after treatment

Read the full 225 word article

How to gain access

Continue reading with a
two-week free trial.